₹916 Cr
3.15
₹291 Cr
As on 13-Aug-2024 IST
₹-18.50
•
-10.62%
₹174.23
₹159.00
₹164.29
₹152.40
21,95,530
₹81.85 - 186.00
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Ind-Swift Lab
| 50.39 | 15.77 | 44.06 | 67.09 | 27.58 | 35.69 | 15.49 |
|
BSE Healthcare
| 30.05 | 6.86 | 18.26 | 46.79 | 16.31 | 26.45 | 12.81 |
|
BSE Small Cap
| 24.81 | -1.39 | 17.32 | 50.92 | 26.42 | 33.21 | 18.27 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Ind-Swift Lab
| 49.10 | 2.21 | 3.98 | 160.46 | -51.85 | -35.26 | 111.60 |
|
BSE Small Cap
| 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 | 59.64 |
|
BSE Healthcare
| 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 | 0.49 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Ind-Swift Laboratories Ltd stood at ₹ 1,165 Cr as on 30-Jun-24
The share price of Ind-Swift Laboratories Ltd is ₹155.73 (NSE) and ₹155.10 (BSE) as of 13-Aug-2024 IST. Ind-Swift Laboratories Ltd has given a return of 27.58% in the last 3 years.
Ind-Swift Laboratories Ltd has a market capitalisation of ₹ 916 Cr as on 13-Aug-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Ind-Swift Laboratories Ltd is 0.98 times as on 13-Aug-2024, a 72% discount to its peers’ median range of 3.50 times.
The P/E ratio of Ind-Swift Laboratories Ltd is 3.15 times as on 13-Aug-2024, a 93% discount to its peers’ median range of 47.46 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Ind-Swift Laboratories Ltd and enter the required number of quantities and click on buy to purchase the shares of Ind-Swift Laboratories Ltd.
Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and advanced intermediates in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, and antineoplastic, as well as various products for ADHD symptoms. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company also exports its products. The company was incorporated in 1995 and is headquartered in Manimajra, India.
The promoters of Ind-Swift Laboratories Ltd are ESSIX BIOSCIENCES LIMITED and N.R. MUNJAL. They collectively own 39.35 per cent of the total equity. The chairman of the company is N R Munjal
There is no promoter pledging in Ind-Swift Laboratories Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
11,208
|
|
|
8,248
|
|
|
7,943
|
|
|
4,730
|
| Ind-Swift Laboratories Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
5.24
|
|
Operating margin(%)
|
3.06
|
|
Net Margin(%)
|
27.62
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of Ind-Swift Laboratories Ltd was ₹291 Cr.
₹916.44 Cr
₹1,003.73 Cr
₹290.83 Cr
₹431.93 Cr
₹851.99 Cr
42.00%
High
₹81.85 - 186.00
₹10.00
5,90,86,860
BSE: 532305, NSE: INDSWFTLAB
Chandigarh, Union Territory
www.indswiftlabs.com
Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and advanced intermediates in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular,... antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, and antineoplastic, as well as various products for ADHD symptoms. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company also exports its products. The company was incorporated in 1995 and is headquartered in Manimajra, India. Read more
Stocks 
Ind-Swift Laboratories Ltd.
Widely used:
